Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Pharma Mar SA ( (ES:PHM) ) has shared an update.
PharmaMar Group reported a 19% increase in recurring income, reaching 37.8 million euros in Q1 2025, driven by strong sales of lurbinectedin in Europe and the U.S. The company also saw a 22% rise in net sales and a 16% increase in royalty income. Despite a decrease in R&D investment, the financial results reflect positive growth in the oncology segment, with implications for sustained market presence and stakeholder confidence.
More about Pharma Mar SA
PharmaMar SA is a pharmaceutical company specializing in the development and commercialization of oncology drugs. Its primary products include Zepzelca® (lurbinectedin) and Yondelis® (trabectedin), with a strong market focus in Europe and the U.S.
YTD Price Performance: 11.88%
Average Trading Volume: 1,304
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.56B
See more insights into PHM stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue